Study Evaluating Mitoxantrone in Multiple Sclerosis

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Mitoxantrone

Criteria

Inclusion Criteria:

• Secondary progressive MS in an active stage

• EDSS between 3 and 6

Exclusion Criteria:

• Benign or primary progressive MS

• Patients with cardiac risk factors

• Patients who have already received mitoxantrone